A 2022 randomized, sham-controlled trial of 73 long COVID patients found that 40 HBOT sessions produced significant cognitive gains, with the global cognitive score improving at p=0.0002 and matching increases in brain perfusion on MRI (Zilberman-Itskovich et al., Scientific Reports). Similar cognitive impairment follows concussion and accompanies chronic fatigue syndrome. HBOT appears to work by driving dissolved oxygen into brain regions with reduced blood flow.
What is brain fog at the cellular level?
Brain fog is not a diagnosis. It is a symptom cluster: trouble concentrating, poor short-term memory, slow processing, word-finding difficulty, and a general sense of mental cloudiness. The underlying pathology differs by condition, but three mechanisms recur across most causes.
Neuroinflammation appears in nearly every condition tied to brain fog. Activated microglia release pro-inflammatory cytokines that disrupt synaptic function. PET imaging with TSPO tracers has shown widespread microglial activation in long COVID patients.
Cerebral hypoperfusion (reduced brain blood flow) has been documented after COVID using SPECT and perfusion MRI, and the regions with the most reduced flow tend to match the cognitive domains most affected. Mitochondrial dysfunction impairs brain energy production; neurons consume roughly 20% of the body’s oxygen despite being about 2% of body weight, so they degrade quickly when energy supply falls.
HBOT targets all three. For a closer look at the cognitive applications, see our analysis of HBOT for cognitive impairment.
How does HBOT work for brain fog?
At 1.5 to 2.0 ATA breathing 100% oxygen, plasma oxygen rises roughly 10 to 15-fold, driving oxygen into brain tissue through diffusion gradients that bypass compromised microcirculation. The documented effects include:
- Increased cerebral oxygenation: brain tissue oxygen can rise from a normal 30 to 40 mmHg to well above 200 mmHg, reaching poorly perfused regions
- Reduced neuroinflammation: suppression of NF-kB signaling and microglial activation, lowering IL-1B, IL-6, and TNF-alpha
- Angiogenesis: repeated sessions stimulate VEGF and HIF-1 alpha, promoting new vessels in hypoperfused areas
- Neuroplasticity: upregulation of BDNF and synaptogenesis
- Mitochondrial biogenesis: intermittent hyperoxia triggers PGC-1 alpha expression
Efrati and Ben-Jacob (2014) describe this as the “hyperoxic-hypoxic paradox,” where fluctuating oxygen levels trigger regenerative signaling normally reserved for low-oxygen states.5
Does HBOT actually work for brain fog?
Post-COVID brain fog
The strongest evidence comes from COVID-related cognitive dysfunction. Zilberman-Itskovich et al. (2022), published in Scientific Reports, ran a randomized, sham-controlled, double-blind trial of 73 long COVID patients with cognitive symptoms persisting more than three months after infection.1
The HBOT group received 40 sessions at 2.0 ATA for 90 minutes. Results showed statistically significant improvements in:
- Global cognitive score (p = 0.0002)
- Attention and executive function (p = 0.004)
- Information processing speed (p = 0.0001)
- Brain perfusion on MRI, correlating with the cognitive gains
The imaging pattern is consistent across this literature: brain regions with reduced blood flow show increased perfusion after a treatment course, and the perfusion changes track the reported cognitive improvement. That correlation, seen on SPECT in the concussion studies below and on MRI in the COVID trial, is the mechanistic thread running through the evidence.
Post-concussion brain fog
| Study | Patients | Protocol | Cognitive outcome |
|---|---|---|---|
| Harch et al., 2012 | 16 military TBI patients | 40 sessions, 1.5 ATA | Improved memory, attention, and processing speed |
| Boussi-Gross et al., 2013 | 56 post-concussion patients | 40 sessions, 1.5 ATA | Improved memory and executive function; SPECT showed increased perfusion |
| Efrati et al., 2015 | 60 fibromyalgia patients with cognitive symptoms | 40 sessions, 2.0 ATA | Improved cognition; brain SPECT changes in frontal and parietal regions |
Harch et al. (2012) and Boussi-Gross et al. (2013) both reported cognitive gains after 40 low-pressure sessions in blast and mild-TBI patients.23 Efrati et al. (2015) studied fibromyalgia rather than concussion, but its 60-patient cohort showed the same pattern of cognitive improvement alongside SPECT changes, which is why it is relevant to the “fibro fog” many patients describe.4
Chronic fatigue-related brain fog
Brain fog is a defining symptom of chronic fatigue syndrome (ME/CFS). No large RCT has tested HBOT specifically for ME/CFS-related cognition, so the evidence here is emerging rather than established. The overlap in pathophysiology with long COVID (neuroinflammation, hypoperfusion, mitochondrial dysfunction) is the rationale for expecting benefit, and several small case series have reported cognitive improvement alongside reduced fatigue. That is a mechanistic argument supported by adjacent data, not direct proof.
What are the typical treatment protocols?
| Parameter | Post-COVID | Post-concussion | General brain fog |
|---|---|---|---|
| Pressure | 2.0 ATA | 1.5 to 2.0 ATA | 1.5 ATA |
| Session duration | 90 minutes | 60 to 90 minutes | 60 minutes |
| Frequency | 5 days/week | 5 days/week | 3 to 5 days/week |
| Total sessions | 40 | 40 to 60 | 40 |
| Typical timeline to improvement | After 15 to 20 sessions | After 20 to 30 sessions | After 20 sessions |
These protocols mirror the ones used in the trials above. Because HBOT carries specific contraindications, anyone considering it should review the contraindications and general oxygen therapy safety precautions first, particularly with ear, sinus, lung, or cardiovascular conditions.
How much does HBOT for brain fog cost?
HBOT for brain fog typically costs $150 to $300 per session. A full course of 40 to 60 sessions runs $6,000 to $18,000. Brain fog is not an FDA-cleared indication, so insurance rarely covers it. Some clinics offer package pricing that lowers the per-session cost by 10% to 20%, and a subset of patients report meaningful improvement by session 20, which can justify a shorter initial course with reassessment before continuing.
Who is a good candidate for HBOT?
HBOT for brain fog is most likely to help patients who have a clear trigger (COVID, concussion, or documented chronic fatigue), show cerebral hypoperfusion on imaging, have not responded to standard care such as cognitive rehabilitation, and can commit to 40 or more sessions over 8 to 12 weeks. It is less likely to help when brain fog stems from poor sleep, medication side effects, untreated depression, or thyroid dysfunction, which should be addressed first. If your cognitive symptoms followed a COVID infection specifically, our guide to HBOT for lingering COVID-19 symptoms and the dedicated long COVID brain fog page cover the protocol in more detail.
Is HBOT worth trying for brain fog?
HBOT targets the cellular mechanisms behind cognitive dysfunction: neuroinflammation, cerebral hypoperfusion, and mitochondrial dysfunction. The evidence is strongest for post-COVID brain fog, where one well-designed sham-controlled RCT showed significant gains across multiple cognitive domains, and supportive for post-concussion symptoms. It is weakest for ME/CFS, where no dedicated RCT exists. The treatment demands a real investment of time and money and is rarely covered by insurance. For patients with persistent, debilitating cognitive symptoms that have not responded to other options, it is a biologically rational choice with growing but still incomplete clinical support. For related cognitive applications, see our overview of the hyperbaric chamber for brain health.
Sources
- Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Scientific Reports. 2022;12:11252. doi:10.1038/s41598-022-15565-0
- Harch PG, Andrews SR, Fogarty EF, et al. A phase I study of low-pressure hyperbaric oxygen therapy for blast-induced post-concussion syndrome and post-traumatic stress disorder. Journal of Neurotrauma. 2012;29(1):168-185. doi:10.1089/neu.2011.1895
- Boussi-Gross R, Golan H, Fishlev G, et al. Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury. PLoS ONE. 2013;8(11):e79995. doi:10.1371/journal.pone.0079995
- Efrati S, Golan H, Bechor Y, et al. Hyperbaric oxygen therapy can diminish fibromyalgia syndrome: prospective clinical trial. PLoS ONE. 2015;10(5):e0127012. doi:10.1371/journal.pone.0127012
- Efrati S, Ben-Jacob E. Reflections on the neurotherapeutic effects of hyperbaric oxygen. Expert Review of Neurotherapeutics. 2014;14(3):233-236. doi:10.1586/14737175.2014.884928
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
